Genmab A/S (GMAB) shareholders
Close on Nov 17, 2026
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 3,707,346 | 5.60% | 13G (passive) amendment | Mar 31, 2025 |
| Darwin Global Management, Ltd. Joint filing with Dr. Abhishek Trehan (5.90%), Darwin Global Master Fund, Ltd. (5.70%) | 3,668,310 | 5.90% | 13G (passive) | Sep 28, 2026 |
| Orbis Investment Management Ltd | 3,320,695 | 5.30% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of GMAB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Paradigm Biocapital Advisors LP | 13,133,131 | 20.40% | $360.77M | +5,165,295 | 6.76% |
| Orbis Allan Gray Ltd | 11,368,161 | 17.66% | $312.28M | −1,557,417 | 1.07% |
| Alliancebernstein L.P. | 8,644,877 | 13.43% | $231.94M | −912,272 | 0.08% |
| Deerfield Management Company, L.P. (Series C) | 6,865,000 | 10.66% | $188.58M | +4,403,000 | 1.97% |
| Deep Track Capital, LP | 5,650,000 | 8.78% | $155.21M | +1,986,750 | 2.26% |
| Arrowstreet Capital, Limited Partnership | 4,975,324 | 7.73% | $136.67M | – | 0.06% |
| BlackRock, Inc. | 4,671,252 | 7.26% | $128.32M | +134,687 | 0.00% |
| Sofinnova Investments, Inc. | 4,045,215 | 6.28% | $111.12M | +3,292,954 | 5.74% |
| Renaissance Technologies LLC | 3,517,850 | 5.46% | $96.64M | −896,700 | 0.13% |
| Two Sigma Investments, LP | 3,506,843 | 5.45% | $96.33M | +1,167,411 | 0.07% |
| Harding Loevner LP | 3,086,318 | 4.79% | $86.90M | −145,283 | 0.82% |
| First Trust Advisors LP | 2,756,522 | 4.28% | $75.72M | +295,180 | 0.04% |
| Citadel Advisors LLC | 2,475,991 | 3.85% | $68.02M | New | 0.01% |
| Qube Research & Technologies Ltd | 1,689,284 | 2.62% | $46.40M | +1,011,938 | 0.04% |
| Morgan Stanley | 1,630,161 | 2.53% | $44.78M | −554,540 | 0.00% |
| Federated Hermes, Inc. | 1,449,376 | 2.25% | $39.81M | +197,786 | 0.06% |
| Goldman Sachs Group Inc | 1,279,231 | 1.99% | $35.14M | +347,972 | 0.00% |
| Franklin Resources Inc | 1,202,923 | 1.87% | $33.04M | +9,778 | 0.01% |
| Pictet Asset Management Holding SA | 1,065,927 | 1.66% | $29.28M | −11,544 | 0.03% |
| UBS Group AG | 961,053 | 1.49% | $26.40M | +662,921 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 290 | 102M | 100.0% | 50 / 102 | 100 / 30 | 26M | 5M |
| Q1 2026 | 275 | 82M | 100.0% | 44 / 105 | 95 / 59 | 18M | 8M |
| Q4 2025 | 293 | 73M | 100.0% | 77 / 121 | 55 / 29 | 17M | 5M |
| Q3 2025 | 253 | 62M | 96.2% | 66 / 99 | 63 / 28 | 12M | 14M |
| Q2 2025 | 218 | 64M | 99.2% | 38 / 82 | 74 / 36 | 10M | 11M |
| Q1 2025 | 220 | 65M | 100.0% | 37 / 92 | 67 / 41 | 14M | 9M |
| Q4 2024 | 229 | 61M | 94.5% | 51 / 76 | 75 / 42 | 18M | 9M |
| Q3 2024 | 224 | 52M | 81.3% | 30 / 98 | 65 / 24 | 10M | 1M |
| Q2 2024 | 220 | 49M | 75.8% | 27 / 68 | 94 / 34 | 4M | 5M |
| Q1 2024 | 227 | 50M | 77.6% | 42 / 88 | 72 / 40 | 5M | 3M |
| Q4 2023 | 226 | 48M | 74.3% | 43 / 54 | 103 / 46 | 10M | 9M |
| Q3 2023 | 234 | 48M | 73.8% | 41 / 96 | 56 / 21 | 8M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
44 funds held GMAB in Q2 2026, 54% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of GMAB | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Biotechnology ETF | 3,701,095 | 5.75% | $101.67M | 1.12% | Jun 30, 2026 |
| First Trust NYSE Arca Biotechnology Index Fund | 2,686,600 | 4.17% | $73.80M | 2.62% | Jun 30, 2026 |
| Ab Large Cap Growth Fund Inc | 1,692,412 | 2.63% | $46.49M | 0.20% | Jun 30, 2026 |
| Federated Hermes Kaufmann Fund | 520,700 | 0.81% | $15.03M | 0.31% | Jul 31, 2026 |
| Avantis International Equity ETF | 512,663 | 0.80% | $13.50M | 0.08% | May 31, 2026 |
| Federated Hermes Kaufmann Small Cap Fund | 350,000 | 0.54% | $10.10M | 0.35% | Jul 31, 2026 |
| Federated Hermes International Leaders Fund | 343,771 | 0.53% | $9.05M | 0.59% | May 31, 2026 |
| Tax-Managed U.S. Large Cap Fund | 342,344 | 0.53% | $9.88M | 0.08% | Jul 31, 2026 |
| Mercer Non-US Core Equity Fund | 179,676 | 0.28% | $4.94M | 0.10% | Jun 30, 2026 |
| SA AB Growth Portfolio | 161,398 | 0.25% | $4.66M | 0.26% | Jul 31, 2026 |
| Tema Oncology ETF | 158,861 | 0.25% | $4.18M | 2.37% | May 31, 2026 |
| LVIP AllianceBernstein Large Cap Growth Fund | 157,566 | 0.24% | $4.33M | 0.27% | Jun 30, 2026 |
| Timothy Plan International Fund | 137,000 | 0.21% | $3.76M | 1.59% | Jun 30, 2026 |
| AB Large Cap Growth Portfolio | 105,277 | 0.16% | $2.89M | 0.28% | Jun 30, 2026 |
| U.S. Strategic Equity Fund | 104,293 | 0.16% | $3.01M | 0.10% | Jul 31, 2026 |
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Genmab A/S's stock actually held short. Settlement fails (shares not delivered on time) peaked at 36,255 shares on Oct 1, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Klimovsky Judith V. Officer | Nov 10, 2026 | 1,265 | $704.33K | Nov 10, 2026 | Stock Award |
| Klimovsky Judith V Director | Jun 17, 2025 | 1,300 | $67.20K | Jun 17, 2025 | Stock Award |
| Klimovsky Judith V Officer | Mar 1, 2024 | 1,200 | $330.00K | Mar 1, 2024 | Stock Award |
See a number that looks wrong?